Obrosova I G, Fathallah L
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0354, USA.
Diabetologia. 2000 Aug;43(8):1048-55. doi: 10.1007/s001250051488.
AIMS/HYPOTHESIS: Aldose reductase inhibitors (ARIs) prevent biochemical abnormalities associated with diabetic complications. We evaluated whether a short-term intervention with an adequate dose of ARI, introduced at the very early, precataractous stage, reversed diabetes-induced metabolic imbalances, down-regulation of ATPases and oxidative stress in the lens. Methods. The groups included mature control and streptozotocin-diabetic rats treated with or without ARI sorbinil (65 mg x kg(-1) x day(-1), in the diet, for 2 weeks after 4 weeks of untreated diabetes). Free cytosolic NAD+:NADH and NADP+:NADPH ratios were calculated from the lactate dehydrogenase and malic enzyme systems. Concentrations of metabolites and adenine nucleotides, Na+/K+-ATPase, H+-ATPase and Ca++-independent Mg++-ATPase activities and variables of oxidative stress were measured in individual lenses. Results. Sorbinil treatment essentially corrected diabetes-induced sorbitol and fructose accumulation, myo-inositol depletion, decrease in free cytosolic NAD+:NADH ratio and energy deficiency. Malondialdehyde accumulation, reduced glutathione depletion and the increase in oxidized glutathione:reduced glutathione ratio were partially corrected. Free cytosolic NADP+:NADPH ratio and 4-hydroxyalkenal concentrations were similarly increased in diabetic rats treated with or without ARI. Sorbinil did not counteract diabetes-induced down-regulation of the three ATPase activities.
CONCLUSION/INTERPRETATION: All biochemical changes assessed in our study are known to be prevented by ARIs. Despite the essential normalization of the sorbitol pathway activity, only part of them were, however, reversed by the ARI treatment introduced at the very early, i.e. precataractous, stage of diabetes. Therefore, intervention studies can easily underestimate the importance of aldose reductase in the pathogenesis of diabetic complications and should be interpreted with caution.
目的/假设:醛糖还原酶抑制剂(ARIs)可预防与糖尿病并发症相关的生化异常。我们评估了在白内障前期极早期阶段采用适当剂量的ARI进行短期干预,是否能逆转糖尿病引起的晶状体代谢失衡、ATP酶下调和氧化应激。方法:研究组包括成熟对照大鼠以及经链脲佐菌素诱导的糖尿病大鼠,糖尿病大鼠在未经治疗4周后,给予或不给予ARI索比尼尔(65 mg·kg⁻¹·天⁻¹,加入饮食中,持续2周)。通过乳酸脱氢酶和苹果酸酶系统计算游离胞质NAD⁺:NADH和NADP⁺:NADPH比值。测量单个晶状体中代谢物和腺嘌呤核苷酸的浓度、Na⁺/K⁺ - ATP酶、H⁺ - ATP酶和Ca²⁺非依赖性Mg²⁺ - ATP酶活性以及氧化应激变量。结果:索比尼尔治疗基本纠正了糖尿病引起的山梨醇和果糖积累、肌醇耗竭、游离胞质NAD⁺:NADH比值降低以及能量缺乏。丙二醛积累、还原型谷胱甘肽耗竭以及氧化型谷胱甘肽:还原型谷胱甘肽比值增加得到部分纠正。给予或未给予ARI治疗的糖尿病大鼠中,游离胞质NADP⁺:NADPH比值和4 - 羟基烯醛浓度同样升高。索比尼尔并未抵消糖尿病引起的三种ATP酶活性下调。
结论/解读:我们研究中评估的所有生化变化已知可被ARIs预防。尽管山梨醇途径活性基本恢复正常,但在糖尿病极早期即白内障前期阶段采用ARI治疗仅逆转了其中部分变化。因此,干预研究可能容易低估醛糖还原酶在糖尿病并发症发病机制中的重要性,对此类研究的解读应谨慎。